NCT05106127: An ongoing trial by Evergreen Therapeutics, Inc.
This trial is ongoing. It must report results 2 years, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05106127 |
|---|---|
| Title | A Phase 2, Open-Label, Safety Lead-In With Long Term Safety Study of EG-007, Added to the Combination of Lenvatinib Plus Pembrolizumab |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 31, 2026 |
| Completion date | March 31, 2027 |
| Required reporting date | March 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |